Health Catalyst, a Nasdaq-listed healthcare intelligence company based in Salt Lake City, has agreed to sell its Vitalware business unit to revenue cycle management firm Med-Metrix for $147 million in cash. The deal, announced on 4 June 2026, marks a significant narrowing of the company's commercial footprint as it seeks to concentrate on its core technology and AI products.

Vitalware, which generated approximately $37 million in revenue in its 2025 fiscal year, provides software used by hospitals and health systems to manage financial operations. Its products cover coding compliance, chargemaster management, charge capture, and price transparency. Med-Metrix, which serves provider organisations across the United States, will take on the business in a transaction that remains subject to regulatory approval. Both parties expect it to close before the end of 2026.

Health Catalyst's chief executive, Ben Albert, described the sale as a step forward for the company. "We are concentrating our business around the areas where we have the deepest conviction, and we plan to put the capital structure in place to back our long-term strategy," he stated.  "Vitalware is a great business, and we are pleased to have found a partner in Med-Metrix who is well positioned to carry it forward."

The proceeds will be used primarily to retire existing debt. Health Catalyst had approximately $160 million in outstanding principal on a senior secured term loan as of 31 March 2026. The company intends to fully repay and terminate that facility using net proceeds from the sale combined with cash on hand, with residual funds covering interest, prepayment premiums, and associated costs. Clearing that obligation is expected to give the company greater financial flexibility as it pursues its stated technology agenda.

Vitalware's software addresses what the industry terms the mid-revenue cycle, the administrative and financial processes that sit between a patient's clinical encounter and the final billing stage. Though profitable and well-regarded, this work is distinct from what Health Catalyst considers its strategic territory. The company has built its positioning around 18 years of proprietary healthcare outcomes data and claims $2.8 billion in documented measurable improvements delivered to health system clients. Its AI development work is oriented towards helping health systems identify and act on operational and clinical improvements, not financial coding or chargemaster functions.

Med-Metrix, by contrast, is already embedded in revenue cycle management. The company works with provider organisations on the administrative and financial infrastructure of healthcare delivery, making Vitalware a logical addition to its existing portfolio. Taking on a business with established clients, recognised software, and a record in coding compliance fits the direction Med-Metrix was already moving in.

The transaction reflects a broader pattern in healthcare technology. There is currently demand on smaller and mid-size vendors who built up product lines during periods of expansion to clarify their positions.  The emergence of AI as a genuine operational tool in healthcare has raised the stakes: companies that cannot make a clear case for how their technology integrates with AI-driven workflows risk being overlooked by health systems that are consolidating their vendor relationships. Health Catalyst has made AI central to its forward strategy, arguing that its proprietary outcomes data gives it an edge that software focused on billing and coding cannot replicate.

The deal is subject to the expiration or termination of regulatory waiting periods under standard antitrust provisions. Raymond James acted as financial adviser to Health Catalyst on the transaction, with law firm Latham and Watkins providing legal counsel. Further detail on the terms is set out in a Form 8-K filed by Health Catalyst with the US Securities and Exchange Commission on 4 June 2026. Health Catalyst's most recent quarterly report, covering the period to 31 March 2026, was filed with the SEC on 11 May 2026 and contains the risk disclosures relevant to the transaction.

‍